A practical RA Q&A about screening risk, cost, and the limits of current evidence.
This RA faculty Q&A centers on clinical uncertainty, moving from MUC5B testing to the more practical question of who should be screened for interstitial lung disease.
Rheumatology evidence, translated for clinic.
Rheumnow Podcast tracks rheumatology evidence as it moves from reports and meetings into practical clinical judgment. Episodes connect topics like psoriatic arthritis, lupus pregnancy risk, obesity, depression, AI documentation tools, and RA-associated lung disease to decisions clinicians face in practice.
PRESS PLAY
Rheumnow Podcast is a clinical rheumatology update show built for people who already live close to the evidence. It treats studies, regulatory decisions, conference sessions, and prescribing habits as working material rather than medical news for casual consumption. The format shifts. Some episodes are weekly briefings led by Jack Cush, while others are captured sessions, panels, or sponsored educational discussions from RheumNow Live and related programming. The through-line is practical interpretation. A report on AI scribes becomes a question about documentation burden and whether ambient dictation actually improves the work of care. Public health statistics on obesity become relevant to rheumatology because BMI, GLP-1 data, inflammation, function, and treatment response do not stay in separate lanes. Mental health appears the same way, not as a side issue but as a factor that can complicate clinical outcomes. The show is especially strong around overlap zones. Dermatology and rheumatology meet through psoriasis, psoriatic arthritis, lupus, vasculitis, hidradenitis, connective tissue disease, biologics, JAK inhibitors, and IL-23 therapy. Pregnancy in lupus is handled through registry evidence, antibody status, fetal loss, pulse steroids, and the limits of association. Psoriatic arthritis episodes use GRAPPA domains and drug-label cautions to frame therapeutic choices. Rheumatoid arthritis panels slow down around risk stratification, including MUC5B testing, interstitial lung disease screening, CT scans, dental disease, and the gap between guidelines and what clinicians will actually do. Conference material widens the scope further, with osteoarthritis disease modification, IL-1 beta inhibition, colchicine signals, hyperuricemia therapy, myositis antibody testing, and asymptomatic CK. The tone is measured. It rarely chases drama. Its value comes from hearing evidence weighed in the language of real clinical constraint: prevalence, subgroup selection, safety warnings, logistics, trial design, and the uncomfortable possibility that a finding is promising but not yet practice-changing.
Made for: Rheumnow Podcast is for rheumatologists, dermatology-adjacent clinicians, trainees, and other healthcare professionals who want specialty updates with clinical caveats intact. It assumes comfort with acronyms, drug classes, and disease subtypes.
What sets it apart: The show stands apart by treating rheumatology news as a prescribing and risk-stratification problem, not just a headline stream. It pairs weekly evidence review with conference panels and educational sessions that preserve the uncertainty clinicians actually have to manage.
Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com
Like grand rounds with sharper elbows, this gives your rheumatology reading list a clinical reality check.
Press play if you want
Short reviews from the PlayNext desk, based on the episodes we processed.
A practical RA Q&A about screening risk, cost, and the limits of current evidence.
This RA faculty Q&A centers on clinical uncertainty, moving from MUC5B testing to the more practical question of who should be screened for interstitial lung disease.
A careful review of why osteoarthritis trials may miss disease-modifying signals.
Disease modification in osteoarthritis sits at the center of this episode, with the discussion framed around a stubborn gap between biological promise and clinical proof. Dr.
A practical preview that mixes meeting logistics with a few real rheumatology payoffs.
Jack Cush frames the episode as a practical pointer to Room Now Live, with the clearest value coming from the clinical lineup he spotlights. Rohit Agrawal's step talks on myositis antibodies testing and asymptomatic CK, the lupus segment centered on CLE and CLASI, and the case…
A Chicago ACR dispatch that keeps the data front and center while staying careful about what the findings can support.
Richard Conway opens this ACR 2025 dispatch with abstract 2359 from Consta et al, a poster on NSAIDs in radiographic axial spondyloarthritis, then moves briskly through a handedness-and-erosion discussion before landing on airway disease in GPA.





Local medicine, told through physicians' lives.

Clinical oncology evidence, translated into treatment decisions.
A rheumatology podcast host promotes the upcoming Room Now Live CME meeting, highlighting its unique features like shorter lectures and extensive Q&A.
This episode features rapid-fire reports from the ACR 2025 conference in Chicago, covering new rheumatology research.
Dr.
An Arctic trial follow-up found DAS remission in 82% of assessed RA patients 10 years after treat-to-target care.
Rheum Now’s “Chikungunya Club Meeting (7.24.2026)” surveys rheumatology news on interstitial lung disease, avacopan, lupus after myocardial infarction, scleroderma, Still’s disease, vaccination, cancer, gout, CPPD, and fibromyalgia.
Rheumnow Podcast’s “Upgrading & Maximizing the Classics” brings Jack Cush together with Angelo Gaffo, Michael Pillinger, Ted Michaels, and Lisa Stamp to examine gout therapy through a survey of more than 220 clinicians in 41 countries.
John Fitzgerald explains how ultrasound reveals silent crystals, erosions, and gout burden patients cannot feel.
Jack Cush discusses the importance of adapting prescribing practices in rheumatology and reviews a study on AI scribes reducing documentation burden.
The host discusses the top four public health problems, focusing on obesity statistics from the CDC and mental health issues from a UK study.
Dr.
Rheumatologists discuss GRAPPA domains and review upetacitinib studies for psoriatic arthritis.
Dr.
Rheumnow Podcast presents STEP Talks from RNL26 Part #1, featuring Tahina Nioji on disease modification in osteoarthritis and Bob Turkeltaub on gout’s history, epidemiology, and treatment development.
Rheumnow Podcast’s “Rheumatoid Arthritis Faculty Panel Q&A” brings Jeff, Kristen, and Elena into a recorded February 7, 2026 discussion of rheumatoid arthritis risk stratification, ILD screening, mucosal hypotheses, and treatment decisions.
Jack Cush promotes the upcoming RheumNow Live conference with top five reasons to attend, including online access, live entertainment, and review questions.
A panel of advanced practice providers discusses the importance of guidelines and co-management in rheumatology cases.
A rheumatology podcast host promotes the upcoming Room Now Live CME meeting by highlighting its unique features like shorter lectures and more Q&A time.
A panel of rheumatology APPs discuss case management and guidelines for nurse practitioners and physician assistants.